Literature DB >> 11742918

Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy.

A J Wolff1, A E O'Donnell.   

Abstract

STUDY
OBJECTIVES: To determine whether the spectrum of HIV-related pulmonary disease seen by a university medical center Pulmonary and Critical Care Medicine Service has changed since the introduction of highly active antiretroviral therapy (HAART).
DESIGN: Retrospective chart review.
SETTING: A tertiary care university hospital. PATIENTS: All HIV-infected patients referred to the Pulmonary and Critical Care Medicine Service from January 1, 1993, through December 31, 1995 (era 1) and from July 1, 1997, through June 30, 2000 (era 2).
INTERVENTIONS: Inpatient and outpatient charts were reviewed for data regarding patient demographics, CD4 cell counts, viral load levels, duration of HIV seropositivity, history of opportunistic infections, and final diagnosis.
RESULTS: Pneumocystis carinii pneumonia (PCP) was less common in the HAART era than in the pre-HAART era, whereas bacterial pneumonia and non-Hodgkin's lymphoma (NHL) were more common in the HAART era than in the pre-HAART era. HAART was protective against PCP (odds ratio [OR], 0.37; confidence interval [CI], 0.16 to 0.89) in a manner dependent on the CD4 cell count. Patients receiving HAART were at increased risk for the development of bacterial pneumonia (OR, 2.41; CI, 1.12 to 5.17) and NHL (OR, 15.11; CI, 3.14 to 28.32). A history of PCP indicated a risk factor for bacterial pneumonia (OR, 2.14; CI, 1.13 to 4.04). A history of cytomegalovirus infection indicated a risk factor for NHL (OR, 6.0; CI, 1.27 to 28.32).
CONCLUSIONS: There have been significant changes in the spectrum of HIV-related pulmonary complications seen by our Pulmonary and Critical Care Medicine Service in the HAART era.

Entities:  

Mesh:

Year:  2001        PMID: 11742918     DOI: 10.1378/chest.120.6.1888

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  27 in total

1.  Pneumonia due to antibiotic resistant Streptococcus pneumoniae and Pseudomonas aeruginosa in the HAART era.

Authors:  S H Allen; P Brennan-Benson; M Nelson; D Asboe; M Bower; B Azadian; B Gazzard; J Stebbing
Journal:  Postgrad Med J       Date:  2003-12       Impact factor: 2.401

Review 2.  Update on opportunistic infections in the era of effective antiretroviral therapy.

Authors:  Brian C Zanoni; Rajesh T Gandhi
Journal:  Infect Dis Clin North Am       Date:  2014-09       Impact factor: 5.982

3.  Changes in the pattern of respiratory diseases necessitating hospitalization of HIV-infected patients since the advent of highly active antiretroviral therapy.

Authors:  Véronique Dufour; Jacques Cadranel; Marie Wislez; Armelle Lavole; Emmanuel Bergot; Antoine Parrot; Pierre Rufat; Charles Mayaud
Journal:  Lung       Date:  2004       Impact factor: 2.584

Review 4.  Th17 cells and mucosal host defense.

Authors:  Shean J Aujla; Patricia J Dubin; Jay K Kolls
Journal:  Semin Immunol       Date:  2007-11-28       Impact factor: 11.130

5.  Measurement of antiretroviral drugs in the lungs of HIV-infected patients.

Authors:  Homer L Twigg; Carol T Schnizlein-Bick; Michael Weiden; Fred Valentine; Joseph Wheat; Richard B Day; Helen Rominger; Lu Zheng; Ronald G Collman; Robert W Coombs; R Pat Bucy; Naser L Rezk; Angela Dm Kashuba
Journal:  HIV Ther       Date:  2010-03-01

Review 6.  HIV-associated lung infections and complications in the era of combination antiretroviral therapy.

Authors:  Kristina Crothers; Bruce W Thompson; Kathryn Burkhardt; Alison Morris; Sonia C Flores; Philip T Diaz; Richard E Chaisson; Gregory D Kirk; William N Rom; Laurence Huang
Journal:  Proc Am Thorac Soc       Date:  2011-06

7.  Prescription of Pneumocystis Jiroveci Pneumonia Prophylaxis in HIV-Infected Patients.

Authors:  Xia Lin; Shikha Garg; Christine L Mattson; Qingwei Luo; Jacek Skarbinski
Journal:  J Int Assoc Provid AIDS Care       Date:  2016-09-14

8.  Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy.

Authors:  Chien-Yu Cheng; Mao-Yuan Chen; Szu-Min Hsieh; Wang-Huei Sheng; Hsin-Yun Sun; Yi-Chun Lo; Wen-Chun Liu; Chien-Ching Hung
Journal:  BMC Infect Dis       Date:  2010-05-21       Impact factor: 3.090

9.  Changes in the socio-demographics, risk behaviors, clinical and immunological profile of a cohort of the Puerto Rican population living with HIV: an update of the Retrovirus Research Center (1992-2008).

Authors:  Christine Miranda; Diana M Fernandez; Raul O Ramon; Miriam Velázquez; Angel M Mayor; Robert F Hunter-Mellado
Journal:  Bol Asoc Med P R       Date:  2010 Jul-Sep

10.  Cellular immune response to pulmonary infections in HIV-infected individuals hospitalized with diverse grades of immunosuppression.

Authors:  M J Miguez-Burbano; D Ashkin; A Rodriguez; R Duncan; M Flores; B Acosta; N Quintero; A Pitchenik
Journal:  Epidemiol Infect       Date:  2006-04       Impact factor: 2.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.